About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Denver | 18,161 Studies Near You | Clareo Health

Clinical Trials LocationsDenver

Clinical Trials in Denver

Discover 18,161 clinical trials near Denver, Colorado. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 4501-4520 of 18,161 trials

COMPLETEDPhase 2< 1 mile

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT02443116

The purpose of this study is to determine the safety, tolerability, and efficacy of NGM282 in patients with nonalcoholic steatohepatitis.

Nonalcoholic Steatohepatitis (NASH)

NGM Biopharmaceuticals, Inc254 participantsStarted Jul 2015

Chandler, Arizona, United States • Tucson, Arizona, United States • Los Angeles, California, United States +19 more locations

TERMINATEDPhase 3< 1 mile

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)

NCT04757610

A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

Neovascular Age-related Macular Degeneration

Opthea Limited986 participantsStarted Mar 2021

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +188 more locations

Find Trials by Condition in Denver

Breast Cancerin Denver Lung Cancerin Denver Prostate Cancerin Denver Colorectal Cancerin Denver Melanomain Denver Leukemiain Denver Lymphomain Denver Pancreatic Cancerin Denver Ovarian Cancerin Denver Brain Cancerin Denver Diabetesin Denver

Data from ClinicalTrials.govTerms

TERMINATEDNA8.4 miles

Secur-Fit Advanced Outcomes Study

NCT01917929

The goal of this study is to evaluate the Secur-Fit Advanced Hip Stem in primary total hip replacement surgery.

Arthroplasty, Replacement, Hip

Stryker Orthopaedics326 participantsStarted Aug 2013

Tucson, Arizona, United States • Aurora, Colorado, United States • Spring Valley, Illinois, United States +5 more locations

TERMINATEDPhase 38.4 miles

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

NCT03744910

This trial investigates the efficacy and safety of clazakizumab \[an anti-interleukin (IL)-6 monoclonal antibody (mAb)\] for the treatment of CABMR in recipients of a kidney transplant.

Antibody-mediated Rejection

CSL Behring194 participantsStarted Oct 2019

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +139 more locations

Enrolling By InvitationPhase 38.4 miles

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

NCT05127954

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate long term safety and tolerability of ubrogepant in the acute treatment of migraine in pediatric participants. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Pediatric participants (aged 6-17 years) with a history of migraine will be enrolled. Participants who completed the lead-in Study 3110-305-002, as well as those who were placebo responders and screen failed, will be eligible to enroll into this study. Around 1200 participants will be enrolled in the study at approximately 120 sites in the United States. Participants may receive ubrogepant oral tables to treat up to 8 migraine attacks of any intensity per month. There will be an option to take a second dose of study intervention (identical to initial dose), or rescue medication, starting 2 hours after the initial dose. The study duration will be up to 54 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The safety and tolerability of the treatment will be checked by medical assessments, blood tests, checking for adverse events and completing questionnaires.

AbbVie1,200 participantsStarted Jan 2022

Huntsville, Alabama, United States • Saraland, Alabama, United States • Little Rock, Arkansas, United States +110 more locations

COMPLETEDPhase 363 miles

Study Evaluating the Safety and Efficacy of AR-15512

NCT05285644

This will be a Phase 3, multicenter, vehicle-controlled, double-masked, randomized study conducted at approximately 20 sites in the United States. All subjects enrolled will have dry eye disease (DED). The study will consist of Screening (Day -14) and Baseline (Day 1) visits as well as visits at Day 7, Day 14, Day 28, and Day 90 (Study Exit) for an individual duration of participation of approximately 15 weeks.

Dry Eye Disease

Aerie Pharmaceuticals465 participantsStarted May 2022

Glendale, California, United States • Torrance, California, United States • Colorado Springs, Colorado, United States +20 more locations

COMPLETEDPhase 363 miles

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

NCT03823287

This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).

Wet Macular Degeneration

Hoffmann-La Roche671 participantsStarted Feb 2019

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +158 more locations

COMPLETEDPhase 4285 miles

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

NCT03915964

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.

Rheumatoid Arthritis

Eli Lilly and Company2,663 participantsStarted Apr 2019

Flagstaff, Arizona, United States • Gilbert, Arizona, United States • Glendale, Arizona, United States +258 more locations

TERMINATEDPhase 3554 miles

Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)

NCT02860130

The purpose of this research is to determine if an investigational new drug solution called Prismocitrate 18 lengthens extracorporeal circuit life in patients treated with continuous renal replacement therapy (CRRT). Patients who receive CRRT treatment with Prismocitrate 18 as the anticoagulant will be compared to patients who receive CRRT treatment with no anticoagulation.

Regional Citrate Anticoagulation (RCA)Continuous Renal Replacement Therapy (CRRT)Acute Kidney Injury

Vantive Health LLC34 participantsStarted Sep 2016

Birmingham, Alabama, United States • Tucson, Arizona, United States • New Haven, Connecticut, United States +9 more locations

COMPLETEDPhase 3556 miles

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

NCT03112174

This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.

Mantle-Cell Lymphoma

Pharmacyclics LLC.366 participantsStarted Jun 2017

Tucson, Arizona, United States • Duarte, California, United States • Los Angeles, California, United States +117 more locations

COMPLETEDPhase 1576 miles

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

NCT03199586

Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.

Breast CancerPancreas CancerProstate Cancer+6 more

Novita Pharmaceuticals, Inc.23 participantsStarted Dec 2017

Scottsdale, Arizona, United States • Duarte, California, United States • New York, New York, United States

COMPLETEDNA580 miles

ROMTECH PortableConnect Rehabilitation Device Usage Post Unilateral Total Knee Arthroplasty (TKA)

NCT04497129

ROMTech is focused on transforming the healthcare market by delivering lower extremity rehabilitation systems that are effective, efficient for patient use, cost-effective, and provide better patient outcomes while simultaneously decreasing rehabilitation and overall recovery times.

Knee OsteoarthritisKnee ArthritisKnee Pain Chronic+4 more

ROM Technologies, INC300 participantsStarted Aug 2020

Gilbert, Arizona, United States • Aventura, Florida, United States • Clearwater, Florida, United States +2 more locations

COMPLETEDNA580 miles

EXOMIND (BTL-699-2) for Improvement of Mental Well-being

NCT06899646

The goal of this clinical trial is to evaluate if the treatment with EXOMIND (BTL-699-2) device is able to improve mental well-being in adults above the age of 22 years. The main question it aims to answer is: Does the treatment with EXOMIND (BTL-699-2) device improve mental well-being? Participants will be asked to: * Undergo four treatments * Complete the Warwick Edinburgh Mental Well-being Scale * Complete the Therapy Comfort Questionnaire * Complete the Subject Satisfaction \& Mental Wellness Questionnaire

Well-Being, Psychological

BTL Industries Ltd.38 participantsStarted Jul 2024

Gilbert, Arizona, United States • Winter Garden, Florida, United States • New York, New York, United States

COMPLETEDPhase 3581 miles

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

NCT02908672

This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab + cobimetinib + vemurafenib compared with placebo + cobimetinib + vemurafenib in patients with previously untreated BRAFv600 mutation-positive metastatic or unresectable locally advanced melanoma.

Hoffmann-La Roche514 participantsStarted Jan 2017

Birmingham, Alabama, United States • Tempe, Arizona, United States • Springdale, Arkansas, United States +107 more locations

COMPLETED693 miles

A Post-market Clinical Study to Collect Safety and Performance Data on Johnson & Johnson Surgical Vision Products

NCT05394324

Retrospective collection of data from medical records, multicenter, post-market clinical follow-up study.

Refractive ErrorGlaucomaCataracts+1 more

Johnson & Johnson Surgical Vision, Inc.1,674 participantsStarted Jun 2022

Dothan, Alabama, United States • Bakersfield, California, United States • Bloomington, Minnesota, United States +10 more locations

COMPLETEDPhase 1/2821 miles

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

NCT04381832

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

Prostatic Neoplasms, Castration-ResistantAndrogen-Resistant Prostatic NeoplasmsCastration Resistant Prostatic Neoplasms+1 more

Arcus Biosciences, Inc.173 participantsStarted Jul 2020

Cerritos, California, United States • Encino, California, United States • Orange, California, United States +16 more locations

TERMINATEDPhase 1/2830 miles

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

NCT06024174

The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC), pancreatic duct adenocarcinoma (PDAC), biliary tract cancer (BTC), or colorectal cancer (CRC).

Advanced Solid Tumors

Bristol-Myers Squibb5 participantsStarted Nov 2023

Los Angeles, California, United States • Athens, Georgia, United States • Hackensack, New Jersey, United States +6 more locations

RECRUITINGNA830 miles

HeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis

NCT06175104

Babies with single ventricle congenital heart disease (SVCHD) are often diagnosed during pregnancy. While prenatal diagnosis has important clinical benefits, it is often stressful and overwhelming for parents, and many express a need for psychological support. HeartGPS is a psychological intervention for parents who receive their baby's diagnosis of SVCHD during pregnancy. It includes 8 sessions with a psychologist, coupled with tailored educational resources, and a personalized care plan. The intervention focuses on fostering parent psychological adjustment and wellbeing, and supporting parents to bond with their baby in ways that feel right for them. Through this study, the investigators will learn if HeartGPS is useful and effective for parents and their babies when it is offered in addition to usual fetal cardiac care. The investigators will examine the effects of the HeartGPS intervention on parental anxiety, depression, and traumatic stress; fetal and infant brain development; parent-infant bonding; and infant neurobehavioral and neurodevelopmental outcomes. The investigators will also explore mechanisms associated with stress biology during pregnancy, infant brain development and neurodevelopmental outcomes, and parent and infant intervention effects.

Heart Defects, CongenitalAnxiety in PregnancyDepression, Postpartum+2 more

Children's Hospital Medical Center, Cincinnati50 participantsStarted Jul 2025

Los Angeles, California, United States • Cincinnati, Ohio, United States • Randwick, New South Wales, Australia +1 more locations

Enrolling By InvitationNA887 miles

Temporally Interfering Electric Field Stimulation in the Treatment of Epilepsy

NCT06716866

This study investigates the potential for temporally-interfering electric field stimulation (TIEFS) to treat epilepsy. In this case series within and between subjects design, the impact of TIEFS on epilepsy biomarkers was studied in patients with medial temporal lobe epilepsy. Secondary analyses examine the underlying physiological effects of TIEF on local brain activity and brain networks.

University of California, Davis100 participantsStarted Jan 2019

Sacramento, California, United States • Atlanta, Georgia, United States • Brno, Czechia

Active Not RecruitingPhase 2914 miles

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT04471974

This phase II trial investigates how well ZEN-3694, enzalutamide, and pembrolizumab work in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). ZEN-3694 blocks the expression of the MYC gene to prevent cellular growth in certain types of tumors, including castrate resistant prostate cancer. Enzalutamide has been shown to block testosterone from reaching prostate cancer cells by binding to a receptor on prostate cancer cells, called androgen receptors. This works similar to a lock and key. When enzalutamide (key) inserts into the androgen receptor (lock) testosterone cannot attach to the androgen receptor, which slows the growth of tumor cells and may cause them to shrink. Pembrolizumab is a monoclonal antibody (proteins that can protect the body from foreign organisms, such as bacteria and viruses) designed to block a specific control switch which may be activated by tumor cells to overcome the body's natural immune system defenses. It also enhances the activity of the body's immune cells against tumor cells. The purpose of this study is to find out the effects ZEN-3694, enzalutamide, and pembrolizumab on patients with metastatic castration-resistant prostate cancer who have previously experienced disease progression.

Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaMetastatic Prostate Small Cell Carcinoma+3 more

Rahul Aggarwal61 participantsStarted Jan 2021

San Francisco, California, United States • Evergreen Park, Illinois, United States • Ann Arbor, Michigan, United States

PreviousPage 226 of 909Next

Heart Diseasein Denver